北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第三临床医学院  > 血液内科  > 期刊论文
学科主题: 临床医学
题名:
A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma
作者: Geng, Chuanying1; Hou, Jian2; Zhao, Yaozhong3,4,5; Ke, Xiaoyan6; Wang, Zhao7; Qiu, Lugui3,4,5; Xi, Hao2; Wang, Fuxu8; Wei, Na7; Liu, Yan6; Yang, Shifang9; Wei, Peng9; Zheng, Xiangjun9; Huang, Zhongxia1; Zhu, Bing9; Chen, Wen-Ming1
刊名: AMERICAN JOURNAL OF HEMATOLOGY
发表日期: 2014-11-01
DOI: 10.1002/ajh.23822
卷: 89, 期:11, 页:1037-1042
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Hematology
研究领域[WOS]: Hematology
关键词[WOS]: APOPTOSIS-INDUCING LIGAND ; APO2L/TRAIL ; CELLS ; LENALIDOMIDE ; CASPASE-8 ; EFFICACY ; THERAPY ; CANCER ; SAFETY ; MEMBER
英文摘要:

Circularly permuted TRAIL (CPT), a recombinant mutant of human Apo2L/TRAIL, is a novel antitumor candidate for multiple myeloma (MM) and other hematologic malignancies. In this phase II study, the safety and efficacy of CPT plus thalidomide was investigated in thalidomide-resistant MM patients. A total of 43 patients were recruited into three CPT plus thalidomide cohorts based on CPT dosage in sequence: 5 mg/kg (n=11), 8 mg/kg (n=17), and 10 mg/kg (n=15). CPT was administered via intravenous infusion on days 1-5, and thalidomide was given orally at 100 mg once daily in each 21-day cycle. The overall response rate (ORR) of 41 efficacy-evaluable patients was 22.0% (2 complete response, 3 near complete response, and 4 partial response). No significant difference in the ORR was observed among the three dose cohorts; however, the ORR tended to be higher with the higher-dose regimen. Median progression-free survival and median duration of response were 6.6 months and 6.1 months, respectively. The most common treatment-related adverse events (TRAEs) were neutropenia (46.5%), leukopenia (41.9%), fever (37.2%), elevated AST (32.6%), and elevated ALT (20.9%). TRAEs of Grade 3-4 were mainly neutropenia (18.6%), anemia (9.3%), elevated AST (7.0%), and leukopenia (4.7%). No significant differences were found in the incidence and severity of TRAEs among the three cohorts. In conclusion, CPT plus thalidomide was well tolerated with no occurrence of dose-limiting toxicities and demonstrated promising antitumor activity in RRMM patients. CPT at 10 mg/kg for 5 days in combination with thalidomide and dexamethason will be studied in the next clinical trial. Am. J. Hematol. 89:1037-1042, 2014. (c) 2014 Wiley Periodicals, Inc.

语种: 英语
项目资助者: Beijing Sunbio Biotechnology Co., Ltd.
WOS记录号: WOS:000344010100009
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/64995
Appears in Collections:北京大学第三临床医学院_血液内科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Capital Med Univ, Beijing Chao Yang Hosp, Dept Hematol, Beijing 100020, Peoples R China
2.Second Mil Med Univ, Chang Zheng Hosp, Dept Hematol, Shanghai, Peoples R China
3.CAMS, Inst Hematol, Dept Lymphoma Ctr, Tianjin, Peoples R China
4.CAMS, Blood Dis Hosp, Tianjin, Peoples R China
5.PUMC, Tianjin, Peoples R China
6.Hebei Med Univ, Hosp 2, Dept Hematol, Hebei, Peoples R China
7.Beijing Sunbio Biotechnol Co Ltd, Beijing, Peoples R China
8.Peking Univ, Dept Hematol, Hosp 3, Beijing 100871, Peoples R China
9.Capital Med Univ, Beijing Friendship Hosp, Dept Hematol, Beijing, Peoples R China

Recommended Citation:
Geng, Chuanying,Hou, Jian,Zhao, Yaozhong,et al. A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma[J]. AMERICAN JOURNAL OF HEMATOLOGY,2014,89(11):1037-1042.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Geng, Chuanying]'s Articles
[Hou, Jian]'s Articles
[Zhao, Yaozhong]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Geng, Chuanying]‘s Articles
[Hou, Jian]‘s Articles
[Zhao, Yaozhong]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace